According to reports from CNBC TV18 and NDTV Profit, AstraZeneca Pharma India reported a 23% year-on-year decline in net profit for the March quarter at ₹44.88 crore, compared with ₹58.25 crore in the corresponding period last year. Despite this profit decline, the pharmaceutical company demonstrated strong revenue performance with revenue from operations rising 20.42% year-on-year to ₹578.61 crore in Q4FY26 from ₹480.48 crore a year earlier. The revenue growth was supported by continued momentum across key therapy segments, as reported by CNBC TV18.
As reported by CNBC TV18, EBITDA declined 29.4% to ₹60.9 crore against ₹86.2 crore in the year-ago quarter, while EBITDA margin contracted sharply to 10.5% from 17.9%. The significant margin compression weighed heavily on profitability despite the robust revenue growth, indicating operational challenges during the quarter. The margin deterioration reflects the impact of lower operating margins on the company's overall profitability metrics. NDTV Profit reports that total expenses of AstraZeneca Pharma India grew 27.36% to ₹525.34 crore in the March quarter, contributing to the margin pressure.
According to latest reports, AstraZeneca Pharma India has announced a generous final dividend of ₹36 per share for FY26, which translates to 1800% of the company's face value of ₹2 per share. This substantial dividend demonstrates the company's commitment to returning value to shareholders despite the challenging quarterly profitability. The board has recommended this dividend subject to shareholder approval, reflecting confidence in the company's long-term financial position.
According to reports from CNBC TV18 and NDTV Profit, for FY26, the company reported total revenue from operations of ₹2,275.58 crore, representing a 32.58% increase from the previous year. The revenue growth was supported by continued growth in Oncology and Biopharmaceuticals, along with progress in the Rare Disease segment. During the year, the company secured 11 new regulatory approvals for medicines and indications in India, demonstrating its continued focus on expanding its therapeutic portfolio. Bhavana Agrawal, Chief Financial Officer and Director, described FY26 as a year of "strong and consistent growth" supported by the company's science-led portfolio and disciplined execution, as reported by CNBC TV18.
According to NDTV Profit, shares of AstraZeneca Pharma India closed ₹8,984.05 per scrip on BSE, up 2.14% from the previous close on Tuesday. The stock had settled at ₹8,795 in the previous session and opened at ₹8,777. During the day, it touched an intra-day high of ₹9,150 and a low of ₹8,751. Over the past 52 weeks, the stock has hit a high of ₹10,653 and a low of ₹7,630. The stock's upper price band stands at ₹10,780, while the lower price band is fixed at ₹7,187. The positive market response suggests investor confidence in the company's long-term growth prospects despite the quarterly margin compression challenges.
